Disease management. A global cost-containing initiative?

Area of Science:

• Health Services Research
• Health Economics
• Pharmaceutical Industry Analysis

Background:

• Disease management (DM) is promoted by healthcare providers for better resource allocation and cost containment.
• The effectiveness and cost-effectiveness of DM strategies are crucial for achieving healthcare efficiency.
• Current DM practices may not always be supported by strong evidence.

Purpose of the Study:

• To critically evaluate the evidence base for disease management programs.
• To analyze the potential economic implications and power dynamics associated with disease management.
• To assess the overall value and risks of disease management in healthcare.

Main Methods:

• Review of evidence from randomized controlled trials and other rigorous evaluations.
• Analysis of economic evaluations concerning disease management interventions.
• Examination of the strategic positioning of pharmaceutical companies within disease management.

Main Results:

• The evidence base for disease management, including randomized controlled trials and economic evaluations, is often inadequate.
• Disease management may represent a strategy of forward vertical integration by pharmaceutical companies.
• Potential benefits like reduced uncertainty and transaction costs may be offset by concentrated power, leading to inflated expenditure and resource misallocation.

Conclusions:

• Disease management initiatives require careful appraisal due to limitations in their evidence base.
• The role of pharmaceutical companies in disease management warrants scrutiny regarding potential conflicts of interest and market power.
• A cautious approach is necessary to ensure disease management truly enhances healthcare efficiency and cost-effectiveness without exacerbating resource misallocation.